A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting target for therapeutic adjuvants. However, STING resides inside the cell, and the intracellular delivery of CDNs, such as cGAMP, is required for the optimal activation of STING. We show that liposomal nanoparticle-delivered cGAMP (cGAMP-NP) activates STING more effectively than soluble cGAMP. These particles induce innate and adaptive host immune responses to preexisting tumors in both orthotopic and genetically engineered models of basal-like TNBC. cGAMP-NPs also reduce melanoma tumor load, with limited responsivity to anti-PD-L1. Within the tumor microenvironment, cGAMP-NPs direct both mouse and human macrophages (M), reprograming from protumorigenic M2-like phenotype toward M1-like phenotype; enhance MHC and costimulatory molecule expression; reduce M2 biomarkers; increase IFN-γ-producing T cells; augment tumor apoptosis; and increase CD4+ and CD8+ T cell infiltration. Activated T cells are required for tumor suppression, as their depletion reduces antitumor activity. Importantly, cGAMP-NPs prevent the formation of secondary tumors, and a single dose is sufficient to inhibit TNBC. These data suggest that a minimal system comprised of cGAMP-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1-insensitive TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Although checkpoint blockade has been groundbreaking in expanding treatment options for multiple solid tumors, less than one-third of patients have a vigorous response (1, 2, 4).”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 8×
“A mammary cell line was derived from the C3(1)/SV40 Tag FVB/NJ–transgenic mice [hereafter referred to as C3(1)Tag mice] and was”
BackgroundMethodInfluentialCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 3×
“Although checkpoint blockade has been groundbreaking in expanding treatment options for multiple solid tumors, less than one-third of patients have a vigorous response (1, 2, 4).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 9×
“We tested M2-like cells because these are frequently found at tumor sites (22).”
BackgroundInfluentialSTING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialTumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialChimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 9×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialDefining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation
Zhong, B., Yang, Y., Li, S., Wang, Y.-Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L., Tien, P., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.003 · Cited by 1,519
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
The cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Differential macrophage programming in the tumor microenvironment
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.12.001 · Cited by 860
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 683
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · cited 8×
“Address correspondence to: Jenny P-Y Ting, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, North Carolina 27514, USA.”
BackgroundInfluentialcGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563
Genard, G., Lucas, S., & Michiels, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00828 · Cited by 419
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
Algazi, A. P., Tsai, K. K., Shoushtari, A. N., Munhoz, R. R., Eroglu, Z., Piulats, J. M., Ott, P. A., Johnson, D. B., Hwang, J., Daud, A. I., et al. (2016) · Cancer · doi:10.1002/cncr.30258 · Cited by 393
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Liposomes for Specific Depletion of Macrophages from Organs and Tissues
van Rooijen, N., & Hendrikx, E. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60327-360-2_13 · Cited by 379
Maroulakou, I. G., Anver, M., Garrett, L., & Green, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11236 · Cited by 363
The origin and function of tumor-associated macrophages
Liu, Y., & Cao, X. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.83 · Cited by 291
Green, J. E., Shibata, M.-A., Yoshidome, K., Liu, M.-L., Jorcyk, C., Anver, M. R., Wigginton, J., Wiltrout, R., Shibata, E., Kaczmarczyk, S., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203280 · Cited by 260
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 253
Self-citationBiodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
Wilson, D. R., Sen, R., Sunshine, J. C., Pardoll, D. M., Green, J. J., & Kim, Y. J. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2017.10.013 · Cited by 220
Emens, L. A., Braiteh, F. S., Cassier, P., Delord, J.-P., Eder, J. P., Fasso, M., Xiao, Y., Wang, Y., Molinero, L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211
Corrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.65 · Cited by 191
Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
Positive Feedback Regulation of Type I IFN Production by the IFN-Inducible DNA Sensor cGAS
Ma, F., Li, B., Liu, S.-Y., Iyer, S. S., Yu, Y., Wu, A., & Cheng, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402066 · Cited by 166
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 162
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 161
The origin and function of tumor-associated macrophages
Yang, Y. Y. Y., Liu, Xuetao, & Cao (2015) · 中国免疫学杂志:英文版 · Cited by 118
Tymoszuk, P., Evens, H., Marzola, V., Wachowicz, K., Wasmer, M., Datta, S., Müller‐Holzner, E., Fiegl, H., Böck, G., van Rooijen, N., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201344304 · Cited by 106
Xia, P., Wang, S., Ye, B., Du, Y., Huang, G., Zhu, P., & Fan, Z. (2015) · Nature Immunology · doi:10.1038/ni.3117 · Cited by 105
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast
Balkwill, F. R., Watling, D., & Taylor‐Papadimitriou, J. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910220307 · Cited by 100
Song, G., Darr, D. B., Santos, C. M., Ross, M., Valdivia, A., Jordan, J. L., Midkiff, B. R., Cohen, S., Nikolaishvili-Feinberg, N., Miller, C. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0493 · Cited by 97
Self-citationErythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal
Zhou, B. R., Damrauer, J. S., Bailey, S. T., Hadzic, T., Jeong, Y., Clark, K. S., Fan, C., Murphy, L. L., Lee, C. Y., Troester, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69804 · Cited by 75
Self-citationChoi, E. A., Lei, H., Maron, D. J., Wilson, J. M., Barsoum, J., Fraker, D. L., El‐Deiry, W. S., & Spitz, F. R. (2003) · PubMed · Cited by 59
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Miao, L., Li, L., Huang, Y., Delcassian, D., Chahal, J., Han, J., Shi, Y., Sadtler, K., Gao, W., Lin, J., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0247-3 · Cited by 723
Self-citationMacrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Metadata
- Authors
- Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., Liu, Q., Miao, L., Huang, L., Bachelder, E. M., Ainslie, K. M., & Ting, J. P.-Y.
- Venue
- JCI Insight
- Published
- 2018-11-15
- Volume
- 3
- Issue
- 22
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2901307735
- Cited by
- 260
- References
- 63
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.